Onconova Therapeutics, Inc. Profile Avatar - Palmy Investing

Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that …

Biotechnology
US, Newtown [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Onconova Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ONTX's Analysis
CIK: 1130598 CUSIP: 68232V801 ISIN: US68232V8019 LEI: - UEI: -
Secondary Listings
ONTX has no secondary listings inside our databases.